OBJECTIVES: Lower incidence rates of distal large bowel cancer in women when compared with men support the protective role of female hormones. We aimed to determine the associations between hormone replacement therapy, oral contraceptive use, and distal large bowel cancer. METHODS: We conducted a population-based case-control study of incident distal large bowel cancer in North Carolina between 2001 and 2006. Data on hormone replacement therapy, oral contraceptive use, demographics, and risk factors were obtained through in-person interviews. Odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between oral contraceptive use, hormone replacement therapy, and distal large bowel cancer were estimated through unconditional logistic regression models overall, by duration of use, and within strata of race. RESULTS: There were a total of 443 women with distal large bowel cancer and 405 controls. Ever use of hormone replacement therapy was strongly associated with a reduced risk of distal large bowel cancer (OR 0.52, 95% CI 0.38-0.72). Further reduction of distal large bowel cancer risk occurred with increased duration of use (<4 years (OR 0.77, 95% CI 0.44-1.35), 4-8 years (OR 0.64, 95% CI 0.37-1.10), 9-14 years (OR 0.47, 95% CI 0.27-0.81), and >or=15 years (OR 0.34, 95% CI 0.20-0.58)). Ever use of oral contraceptives was not associated with reduced incidence of distal large bowel cancer (OR 0.95, 95% CI 0.67-1.34) nor was duration of use. There were no differences by race. CONCLUSIONS: Hormone replacement therapy is associated with a lower risk of distal large bowel cancer. This risk is further reduced with increased duration of use. Hormone replacement therapy may be partially responsible for the reduced incidence of distal large bowel cancer in women compared with men.
OBJECTIVES: Lower incidence rates of distal large bowel cancer in women when compared with men support the protective role of female hormones. We aimed to determine the associations between hormone replacement therapy, oral contraceptive use, and distal large bowel cancer. METHODS: We conducted a population-based case-control study of incident distal large bowel cancer in North Carolina between 2001 and 2006. Data on hormone replacement therapy, oral contraceptive use, demographics, and risk factors were obtained through in-person interviews. Odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between oral contraceptive use, hormone replacement therapy, and distal large bowel cancer were estimated through unconditional logistic regression models overall, by duration of use, and within strata of race. RESULTS: There were a total of 443 women with distal large bowel cancer and 405 controls. Ever use of hormone replacement therapy was strongly associated with a reduced risk of distal large bowel cancer (OR 0.52, 95% CI 0.38-0.72). Further reduction of distal large bowel cancer risk occurred with increased duration of use (<4 years (OR 0.77, 95% CI 0.44-1.35), 4-8 years (OR 0.64, 95% CI 0.37-1.10), 9-14 years (OR 0.47, 95% CI 0.27-0.81), and >or=15 years (OR 0.34, 95% CI 0.20-0.58)). Ever use of oral contraceptives was not associated with reduced incidence of distal large bowel cancer (OR 0.95, 95% CI 0.67-1.34) nor was duration of use. There were no differences by race. CONCLUSIONS: Hormone replacement therapy is associated with a lower risk of distal large bowel cancer. This risk is further reduced with increased duration of use. Hormone replacement therapy may be partially responsible for the reduced incidence of distal large bowel cancer in women compared with men.
Authors: Polly A Marchbanks; Jill A McDonald; Hoyt G Wilson; Suzanne G Folger; Michele G Mandel; Janet R Daling; Leslie Bernstein; Kathleen E Malone; Giske Ursin; Brian L Strom; Sandra A Norman; Phyllis A Wingo; Ronald T Burkman; Jesse A Berlin; Michael S Simon; Robert Spirtas; Linda K Weiss Journal: N Engl J Med Date: 2002-06-27 Impact factor: 91.245
Authors: Frances E Thompson; Amy F Subar; Charles C Brown; Albert F Smith; Carolyn O Sharbaugh; Jared B Jobe; Beth Mittl; James T Gibson; Regina G Ziegler Journal: J Am Diet Assoc Date: 2002-02
Authors: A F Subar; F E Thompson; V Kipnis; D Midthune; P Hurwitz; S McNutt; A McIntosh; S Rosenfeld Journal: Am J Epidemiol Date: 2001-12-15 Impact factor: 4.897
Authors: M L Slattery; J D Potter; K Curtin; S Edwards; K N Ma; K Anderson; D Schaffer; W S Samowitz Journal: Cancer Res Date: 2001-01-01 Impact factor: 12.701
Authors: P Gervaz; H Bouzourene; J P Cerottini; P Chaubert; J Benhattar; M Secic; S Wexner; J C Givel; B Belin Journal: Dis Colon Rectum Date: 2001-03 Impact factor: 4.585
Authors: Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene Journal: JAMA Date: 2002-07-17 Impact factor: 56.272
Authors: Brittany M Charlton; Kana Wu; Xuehong Zhang; Edward L Giovannucci; Charles S Fuchs; Stacey A Missmer; Bernard Rosner; Susan E Hankinson; Walter C Willett; Karin B Michels Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-06-10 Impact factor: 4.254
Authors: Andrea Iannone; Giuseppe Losurdo; Maria Pricci; Bruna Girardi; Antonio Massaro; Mariabeatrice Principi; Michele Barone; Enzo Ierardi; Alfredo Di Leo Journal: J Gastrointest Cancer Date: 2016-06
Authors: Manal M Hassan; Gehan Botrus; Reham Abdel-Wahab; Robert A Wolff; Donghui Li; David Tweardy; Alexandria T Phan; Ernest Hawk; Milind Javle; Ju-Seog Lee; Harrys A Torres; Asif Rashid; Renato Lenzi; Hesham M Hassabo; Yasmin Abaza; Ahmed S Shalaby; Sahin Lacin; Jeffrey Morris; Yehuda Z Patt; Christopher I Amos; Saira A Khaderi; John A Goss; Prasun K Jalal; Ahmed O Kaseb Journal: Clin Gastroenterol Hepatol Date: 2017-06-01 Impact factor: 11.382
Authors: Song-Yi Park; Lynne R Wilkens; Laurence N Kolonel; Brian E Henderson; Loïc Le Marchand Journal: Int J Cancer Date: 2016-05-14 Impact factor: 7.396